Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2024-02-14 Capital/Financing Update
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is related to an initial public offering (IPO) of common stock by Chromocell Therapeutics Corporation. The text includes detailed information about the offering, the shares being registered, underwriters, and legal counsel, which are typical components of a registration statement for securities offerings. This type of filing is a capital markets document related to financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document is not an annual report, earnings release, or any other report type but specifically a registration statement amendment for an IPO.
2024-02-14 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from Chromocell Therapeutics Corporation to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and discusses procedural matters related to the registration statement becoming effective. The document is short (2378 characters) and does not contain financial statements or substantive financial data. It is an announcement related to a regulatory filing process rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-13 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a correspondence letter from A.G.P./Alliance Global Partners to the SEC regarding a Registration Statement on Form S-1. It requests acceleration of the effective date for the registration statement and discusses distribution of the Preliminary Prospectus. This is related to a capital raising process and underwriting activities. The document is not a financial report, earnings release, or management discussion. It is an update on financing activity and regulatory compliance related to a securities offering. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is a formal letter, not a report or announcement of a report publication, so it is not RPA or RNS. Confidence is high due to clear references to underwriting and registration statement acceleration.
2024-02-13 English
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) dated February 12, 2024, filed pursuant to Rule 433 of the Securities Act of 1933. It relates to a preliminary prospectus and registration statement for Chromocell Therapeutics Corporation's offering. The content includes detailed information about the offering size, use of proceeds, capitalization table, investment highlights, clinical development plans, management team, and drug development pipeline. The document is clearly a marketing and disclosure document related to a capital raising event, specifically an IPO. It is not a financial report, earnings release, or regulatory filing of financial results. It is a prospectus-type document used to inform potential investors about the offering and the company. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-02-12 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is related to an initial public offering (IPO) of common stock by Chromocell Therapeutics Corporation. The text includes detailed information about the offering, the shares being registered, the underwriters, and the prospectus. This type of filing is a capital raising document used to register securities for public sale. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the filing itself, not just an announcement. Hence, the classification is CAP with high confidence.
2024-02-12 English
FWP
Capital/Financing Update Classification · 100% confidence The document is an Issuer Free Writing Prospectus (FWP) filed pursuant to Rule 433 of the Securities Act of 1933. It contains detailed information about a company's offering, including transaction overview, capitalization table, investment highlights, clinical development plans, management team, and use of proceeds. The document is focused on providing information related to a securities offering and is not a financial report, earnings release, or regulatory filing of financial results. It is a type of prospectus or offering document used in capital markets to inform potential investors about the offering and the company. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-02-07 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.